Anxiolytic-like effects of meprobamate: Interactions with an opiate antagonist in Swiss and BALB/c mice

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 3, 2000, Pages 465-474

  Belzung, Catherine ^a   Le Guisquet, Anne Marie ^a   Ågmo, Anders ^b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anxiolytic; BALB c mice; Light dark choice procedure; Meprobamate; Opiates; Plus maze test; Swiss mice

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; MEPROBAMATE; NALOXONE; OPIATE ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; MALE; MEPROBAMATE; MICE; MICE, INBRED BALB C; NALOXONE; NARCOTIC ANTAGONISTS; RECEPTORS, GABA-A;

EID: 0033982783     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00228-2     Document Type: Article

References (76)

1. Ågmo A., Belzung C. The role of subtypes of the opioid receptor in the anxiolytic action of chlordiazepoxide. Neuropharmacology. 37:1998;223-232.
2. Ågmo A., Belzung C., Deloire X., Grassin M., Lewis S. Blockade of anxiolytic-like actions of chlordiazepoxide by naloxone in the elevated plus-maze. Comparisons between Swiss, C57BL/6 and BALB/c mice Psychobiology. 27:1999;105-113.
3. Ågmo A., Fernández H. Benzodiazepine receptor ligands and sexual behavior in the male rat. The role of GABAergic mechanisms Pharmacol. Biochem. Behav. 38:1991;781-788.
4. Ågmo A., Galván A., Heredia A., Morales M. Naloxone blocks antianxiety but not the motor effects of benzodiazepines and pentobarbital. Experimental studies and literature review Psychopharmacology (Berlin). 120:1995;186-194.
5. Badia-Elder, N.; Stewart, R. B.; Froehlich, S. C.: Naloxone does not alter the anxiolytic effect of alcohol. Soc. Neurosci. Abstr. 24:579.4; 1998.
6. Belzung C., Ågmo A. Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in BALB/c mice. Psychopharmacology (Berlin). 132:1997;195-201. a.
7. Belzung C., Ågmo A. Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice. Eur. J. Pharmacol. 323:1997;133-136. b.
8. Belzung C., Dubreuil D. Naloxone potentiates the anxiolytic but not the amnestic action of chlordiazepoxide in C57BL/6 mice. Behav. Pharmacol. 9:1998;691-698.
9. Belzung C., Le Guisquet A.M. Different pattern of interaction of three anti-anxiety compounds (chlordiazepoxide, diazepam and buspirone) with naloxone. Behav. Pharmacol. 8:1998;642.
10. Berger F.M. The pharmacological properties of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown), a new interneuronal blocking agent. J. Pharmacol. Exp. Ther. 112:1954;413-423.
11. Billingsley M.L., Kubena R.K. The effects of naloxone and picrotoxin on the sedative and anticonflict effects of benzodiazepines. Life Sci. 22:1978;897-906.
12. Bonetti E.P., Pieri L., Cumin R., Dschaffer R., Pieri M., Gamzu E.R., Muller R.K., Haefely W. Benzodiazepine antagonist Ro 15-1788. Neurological and behavioral effects Psychopharmacology (Berlin). 78:1982;8-18.
13. Brady K.T., Lydiard R.B., Ballenger J.C., Shook J., Laraia M., Fossey M. CSF opioids in panic disorder. Biol. Psychiatry. 30:1991;512-514.
14. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., Lloyd K.L. Major tranquilizers can be distinguished from minor tranquilizers on the base of effects on marble burying and swim-induced grooming in mice. Eur. J. Pharmacol. 126:1986;223-229.
15. Bruns R.F., Katims J.J., Annau Z., Snyder S.H., Daly J.W. Adenosine receptor interactions and anxiolytics. Neuropharmacology. 22:1983;1523-1529.
16. Burov I.V., Borisenko S.A. The effect of neurotropic substances on the self-stimulation reaction at the thalamic level (in Russian). Biull. Eksp. Biol. Med. 81:1976;43-45.
17. Carmody J., Jamieson D., de Poortere R. Opioid-independent hyperalgesia induced in mice be pentobarbitone at low dosage. Naunyn Schmiedebergs Arch. Pharmacol. 334:1986;193-195.
18. Chiou L.C., Ling J.Y., Chang C.C. Enhancement by benzodiazepines of the inhibitory affect of adenosine on skeletal neuromuscular transmission. Br. J. Pharmacol. 116:1995;1870-1874.
19. Cohen G.A., Doze V.A., Madison D.V. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron. 9:1992;325-335.
20. Cooper K.A., Carmody J. The characteristics of the opioid-related analgesia induced by the stress of swimming in mice. Neurosci. Lett. 31:1982;165-170.
21. Crawley J.N. Neuropharmacological specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 15:1981;359-362.
22. Delong R.E., Phillis J.W., Barraco R.A. A possible role of endogenous adenosine in the sedative action of meprobamate. Eur. J. Pharmacol. 118:1985;359-362.
23. Dienstbier R.A., Crabbe J., Johnson G.O., Thorland W., Jorgensen J.A., Sadar M.M., La Velle D.C. Exercise and stress tolerance. Sacks M.H., Sachs M.L. Psychology of running. 1981;193-210 Human Kinetics Publishers, Champaign, IL.
24. Dingledine R., Iversen L.L., Breuker E. Naloxone as a GABA antagonist. Evidence from iontophoretic, receptor binding and convulsant studies Eur. J. Pharmacol. 47:1978;19-27.
25. Duka T., Cumin R., Haefely W., Herz A. Naloxone blocks the effect of diazepam and meprobamate on conflict behavior in rats. Pharmacol. Biochem. Behav. 15:1981;115-117.
26. Duka T., Millan M.J., Ulsamer B., Doenicke A. Naloxone attenuates the anxiolytic action of diazepam in man. Life Sci. 31:1982;1833-1836.
27. Fernández-Guardiola A., Pellicer F., Rocha L., Gutiérrez R. Naloxone facilitates sensory precipitation of focal and generalized seizures - Evoked potentials and and power spectral-analysis in the cat. Exp. Neurol. 101:1988;159-175.
28. 1 receptors modulate anxiety in CD1 mice. Psychopharmacology (Berlin). 136:1998;311-319.
29. Geller I., Seifter J. The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia. 1:1960;482-492.
30. Goldinger A., Müller W.E., Wollert U. Inhibition of glycine and GABA receptor binding by several opiate agonists and antagonists. Gen. Pharmacol. 12:1981;477-479.
31. Griebel G., Belzung C., Misslin R., Vogel E. The free-exploratory paradigm. An effective method for measuring neophobic behavior in mice and testing potential neophobia-reducing drugs Behav. Pharmacol. 4:1993;637-644.
32. Haefely W., Schaffner P., Polc P., Pieri L. General pharmacology and neuropharmacology of propanediol carbamates. Handb. Exp. Pharmacol. 55:1981;263-283.
33. i-adenylatecyclase complex in rat hippocampus. Eur. J. Pharmacol. 154:1988;95-98.
34. Howard J.L., Rohrbach K.W., Pollard G.T. Cumulative dose-effect curves in a conflict test with incremental shock. Psychopharmacology (Berlin). 78:1982;195-196.
35. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116:1995;2127-2133.
36. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarizing local interneurons. J. Neurosci. 12:1992;483-488.
37. Jones L.S. Naloxone blocks antiepileptogenic properties of an in vitro electroconvulsive shock model. Brain Res. 564:1991;336-340.
38. Koob G.F., Strecker R.E., Bloom F.E. Effects of naloxone on the anticonflict properties of alcohol and chlordiazepoxide. Subst. Alcohol Actions/Misuse. 1:1980;447-457.
39. Kopp C., Vogel E., Rettori M.C., Delagrange P., Guardiola-Lemaitre B., Misslin R. Effects of daylight cuycle reversal on locomotor activity on several inbred strains of mice. Physiol. Behav. 63:1998;577-585.
40. Kõks S., Soosaar A., Võkar V., Volke V., Ustav M., Männistö P.T., Bourin M., Vasar E. Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides. 32:1998;235-240.
41. Kramer K., Voss H.P., Grimbergen J., Bast A. Circadian rhythms of heart rate, body temperature, and locomotor activity in freely moving mice measured with radio telemetry. Lab. Anim. 27:1998;23-26.
42. Lenègre A., Avril I., Fromage S., Milinkevitch D., Porsolt R.D. Absence of amnesia induction in mice with hydroxyzine in comparison with three other minor tranquilizers. Arzneimittelforschung. 38:1988;558-560.
43. Liebman J.M. Anxiety, anxiolytics and brain reinforcement. Neurosci. Biobehav. Rev. 9:1985;75-86.
44. Lupica C.R. δ and μ enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic AMP-independent mechanism in the hippocampus. J. Neurosci. 15:1995;737-739.
45. 35S-TSBS binding and GABA enhances their displacing potencies. Life Sci. 43:1988;1331-1337.
46. 1A receptors in membranes from the rat brain. Neuropharmacology. 30:1991;323-327.
47. Metha A.K., Kulkarni S.K. Mechanisms of potentiation by diazepam of adenosine. Life Sci. 34:1984;81-86.
48. Miczek K.A., Thompson M.L. Analgesia resulting from defeat in a social confrontation. The role of endogenous opioids in the brain Bandler R. Modulation of sensorimotor activity during alterations in behavioral states. 1984;431-456 Alan R. Liss, New York.
49. Misslin R., Belzung C., Vogel E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Proc. 18:1989;119-132.
50. Moroi K., Ozaki N., Kadota T., Kadota K. Characterization of [H-3]5-hydroxytryptamine and [H-3]spiperone binding sites in clathrin-coated vesicles from bovine brain. Brain Res. 794:1998;291-298.
51. Onaivi E.S., Martin B.R. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry. 13:1989;964-976.
52. Patel J.B., Martin C., Malick J.B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur. J. Pharmacol. 86:1983;295-298.
53. Paul S.M., Marangos P.J., Skolnick P. The benzodiazepine-GABA-chloride ionophore receptor complex. Common site of minor tranquilizer action Biol. Psychiatry. 16:1983;213-229.
54. Peeler D.F., Nowakowski R.S. Genetic factors and the measurement of exploratory activity. Behav. Neural Biol. 48:1987;90-103.
55. Pellicer F., Rocha L., Gutiérrez R., Fernández-Guardiola A. Epileptogenesis and muscular hypertonic postictal phenomena induced by naloxone in intact cats. Epilepsia. 29:1988;374-378.
56. Phillis J.W. Adenosine's role in the central actions of benzodiazepines. Prog. Neuropsychopharmacol. Biol. Psychiatry. 8:1984;495-502.
57. Phillis J.W., Delong R.E. A purinergic component in the central actions of meprobamate. Eur. J. Pharmacol. 101:1984;295-297.
58. Phillis J.W., O'regan M.H. The role of adenosine in the central actions of the benzodiazepines. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;389-404.
59. Pollard G.T., Howard J.L. The staircase test. Some evidence of nonspecificity of anxiolytics Psychopharmacology (Berlin). 89:1986;14-19.
60. Rho J.M., Donevan S.D., Rogawski M.A. Barbiturate-like actions of propanediol dicarbamates felbamate and meprobamate. J. Pharmacol. Exp. Ther. 280:1997;1383-1391.
61. Sanger D.J., Joly D., Zivkovic B. Behavioral effects of nonbenzodiazepine anxiolytic drugs. A comparison of CGS 9896 and zopiclone with chlordiazepoxide J. Pharmacol. Exp. Ther. 232:1985;831-837.
62. Sarne Y., Fields A., Keren O., Gafni M. Stimulatory effects of opioid transmitter release and possible cellular mechanisms. Overview and original results Neurochem. Res. 21:1996;1353-1361.
63. Shanks N., Griffiths J., Zalcman S., Zacharko R.M., Anisman H. Mouse strain differences in plasma corticosterone following uncontrollable footshock. Pharmacol. Biochem. Behav. 36:1990;515-519.
64. Simiand J., Keane P.E., Morre M. The staircase test in mice. A simple and efficient procedure for primary screening of anxiolytic agents Psychopharmacology (Berlin). 84:1984;48-53.
65. Soubrié P., de Angelis L., Simon P., Boissier J.R. Effets des anxiolytiques sur la prise de boisson en situation nouvelle et familière. Psychopharmacologia. 50:1976;41-45.
66. Soubrié P., Jorbert A., Thiebot M.H. Differential effects of naloxone against the diazepam-induced release of behavior in rats in three aversive situations. Psychopharmacology (Berlin). 69:1980;101-105.
67. Soubrié P., Kulkarni S., Simon P., Boissier J.R. Effets des anxiolytiques sur la prise de nourriture de rats et de souris placés en situation nouvelle et familière. Psychopharmacologia. 45:1975;203-210.
68. Spyraki C., Kazandjian A., Varonos D. Diazepam-induced place preference conditioning. Appetitive and antiaversive properties Psychopharmacology (Berlin). 87:1985;225-232.
69. Sudak H.S., Maas J.W. Central nervous serotonin and norepinephrine localization in emotional and non-emotional strains of mice. Nature. 203:1964;1254-1256.
70. Thompson W.R. The inheritance of behavior. Behavioral differences in fifteen mouse strains Can. J. Psychol. 7:1953;145-155.
71. 1A receptor antagonist, on 8-OH-DPAT responses. Eur. J. Pharmacol. 347:1996;41-49.
72. Trullas R., Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology (Berlin). 111:1993;323-331.
73. Tsuda M., Suzuki T., Misawa M., Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur. J. Pharmacol. 307:1996;7-14.
74. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
75. Zaleska-Freylan K.I. Diurnal changes in the level of blood plasma corticosteroids in laboratory mice in relation to sex and season. Bull. Acad. Polonaise Sci. Series Sci. Biol. 27:1979;571-574.
76. Zangrossi H., Leite J.R., Graeff F.G. Anxiolytic effect of carbamezapine in the elevated plus-maze. Possible role of adenosine Psychopharmacology (Berlin). 106:1992;85-89.